Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Catarina Abreu has a total of 289 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessing the Impact of Comprehensive Genomic Profiling on Therapeutic Selection for Advanced Solid Tumors in Portugal

    by Nuno Tavares, Pedro Simões, Raquel Lopes-Brás, Teresa R. Pacheco, Sara Damaso, Andre Mansinho, Leonor Abreu Ribeiro, Gonçalo Nogueira-Costa, Catarina Abreu, Tiago Barroso, et al.

    Background: Comprehensive genomic profiling (CGP) is a tool used in precision oncology to identify genomic alterations and match them with targeted therapies across several tumor types. However, real-world data on its clinical utility and impact remains limited. The FRONTAL study (Foundation Medicine Real wOrld evideNce in porTugAL) is a multicenter academic initiative that established a national registry of Portuguese patients with solid tumors who underwent CGP with FoundationOne CDx, Liquid CDx or FoundationOne Heme assays. Methods: Eligible patients had advanced solid tumors not suitable for curative treatment at the time of recruitment. Prior CGP testing was permitted if taken within 12 months before study initiation. Genomic profiling data were extracted from FoundationOne Medicine reports, and clinical information was extracted from medical records. Actionable alterations were defined as those associated with approved treatments or with clinical evidence of benefit in other cancers, per NCCN guidelines. Variant interpretation was also reviewed according to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) guidelines. The primary outcome was disease control at 16 weeks, defined by the absence of progression. Results: The study included 205 patients between 2020 and 2025 across 10 sites, with colorectal (40, 19.5%), sarcomas (28, 13.7%), and other gastrointestinal tumors (22, 10.7%) being the most common pathologies. Actionable alterations were identified in 104 cases (50.7%). Genomic findings guided therapy decisions in 50 patients (24.4%), of whom 30 achieved disease control at 16 weeks (14.6%). Conclusions: The FRONTAL study highlighted the clinical relevance of CGP in advanced solid tumors. Over half of the patients had actionable alterations, a quarter had therapy changes based on CGP results, and improved disease outcome was observed in approximately 15% of the cohort.

  • Open Access

    Assessing the Impact of Comprehensive Genomic Profiling on Therapeutic Selection for Advanced Solid Tumors in Portugal

    by Nuno Tavares, Pedro Simões, Raquel Lopes-Brás, Teresa R Pacheco, Sara Damaso, Andre Mansinho, Leonor Abreu Ribeiro, Gonçalo Nogueira-Costa, Catarina Abreu, Tiago Barroso, et al.

    Comprehensive genomic profiling (CGP) is a tool used in precision oncology to identify genomic alterations and match them with targeted therapies across several tumor types. However, real-world data on its clinical utility and impact remains limited. The FRONTAL study (Foundation Medicine Real wOrld evideNce in porTugAL) is a multicenter academic initiative that established a national registry of Portuguese patients with solid tumors who underwent CGP with FoundationOne CDx, Liquid CDx or FoundationOne Heme assays. Methods: Eligible patients had advanced solid tumors not suitable for curative treatment at the time of recruitment. Prior CGP testing was permitted if taken within 12 months before study initiation. Genomic profiling data were extracted from FoundationOne Medicine reports, and clinical information was extracted from medical records. Actionable alterations were defined as those associated with approved treatments or with clinical evidence of benefit in other cancers, per NCCN guidelines. Variant interpretation was also reviewed according to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) guidelines. The primary outcome was disease control at 16 weeks, defined by the absence of progression. Results: The study included 205 patients between 2020 and 2025 across 10 sites, with colorectal (40, 19.5%), sarcomas (28, 13.7%), and other gastrointestinal tumors (22, 10.7%) being the most common pathologies. Actionable alterations were identified in 104 cases (50.7%). Genomic findings guided therapy decisions in 50 patients (24.4%), of whom 30 achieved disease control at 16 weeks (14.6%). Conclusions: The FRONTAL study highlighted the clinical relevance of CGP in advanced solid tumors. Over half of the patients had actionable alterations, a quarter had therapy changes based on CGP results, and improved disease outcome was observed in approximately 15% of the cohort.

  • Open Access

    Table S1 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response

    by Inês Gomes, Maria Martelo, Rúben D. Vilela, María Jiménez, Eva M. Trinidad, Jorge Gómez-Miragaya, Eva González-Suárez, Érica Martins, Sofia S. Torres, Patrícia Corredeira, et al.

    Supplementary Table 1. Molecular characteristics of the human cell lines used in this study.

  • Open Access

    Table S5 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response

    by Inês Gomes, Maria Martelo, Rúben D. Vilela, María Jiménez, Eva M. Trinidad, Jorge Gómez-Miragaya, Eva González-Suárez, Érica Martins, Sofia S. Torres, Patrícia Corredeira, et al.

    Supplementary Table 5. HALLMARK gene set enrichment analysis (GSEA_mh) of mouse allografts (NES>1.5 or <-1.5; NOM p value<0.05; FDR q value<0.25).

  • Open Access

    Figure S1 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response

    by Inês Gomes, Maria Martelo, Rúben D. Vilela, María Jiménez, Eva M. Trinidad, Jorge Gómez-Miragaya, Eva González-Suárez, Érica Martins, Sofia S. Torres, Patrícia Corredeira, et al.

    Supplementary Figure 1 (related to Fig. 1). RANK pathway inhibition sensitizes TNBC cells to CDK4/6i. A, RT–qPCR analysis of RANK in TNBC cell lines (n = 2-3 biological replicates). B, RT–qPCR analysis of RANK in parental, shControl and shRANK MDA-MB-231 cells (n = 3 biological replicates). Western blot analysis of C, p-ERK1/2, D, p-p65 and p-AKT after 15 min of stimulation with 1 μg/mL RANKL neutralized or not with 2.5 μg/mL RANKLi (OPG-Fc or RANK-Fc), with β-actin as a loading control. E, Viability of the indicated cell lines cultured for 7 days in the presence of increasing concentrations of CDK4/6i ± 100 ng/mL OPG-Fc, as measured by the Alamar blue assay (n = 3-4 independent experiments). F, Proliferation of the indicated cell lines cultured in the presence of 1 μM CDK4/6i ± 100 ng/mL RANK-Fc for 7 days and in drug-free media for an additional 7 days, as measured by clonogenic assay (n = 3-6 independent experiments). G, Cell cycle analysis in MDA-MB-231 cell lines cultured with 100 ng/mL OPG-Fc for 7 days (n = 3 independent experiments). The results are presented as the means ± SEMs. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

  • Open Access

    Figure S2 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response

    by Inês Gomes, Maria Martelo, Rúben D. Vilela, María Jiménez, Eva M. Trinidad, Jorge Gómez-Miragaya, Eva González-Suárez, Érica Martins, Sofia S. Torres, Patrícia Corredeira, et al.

    Supplementary Figure 2 (related to Fig. 2). Palbociclib in combination with OPG-Fc restrains tumor growth in vivo. A, IHC analysis of ER, HER2, p-pRb and RANK in PDX tissue, including positive cell line-derived xenograft tissue as positive control for ER and HER2, and representative images at 400X magnification. B, Single tumor growth curves (all treated animals independently of treatment completion, n = 4-5 animals, n = 8-10 tumors in the cell line-derived model, and n = 3-4 animals in the PDX model). Tumors were measured externally with a caliper at the indicated time points, and Tvol = 1/2 (length × width2) was calculated. C, Tumor weight at sacrifice (n = 6-8 tumors in the cell line-derived model, and n = 3-4 tumors in the PDX model). D, Mouse body weight during treatment (n = 3-5 animals). E, Quantification of TRAcP5b in mouse serum by ELISA (n = 2-4 samples/group). F, Venn diagram depicting the overlap between DEGs of MDA-MB-231 tumors treated with OPG-Fc (n = 2), palbociclib (Palbo, n = 2) or palbociclib + OPG-Fc (COMB, combination, n = 3) in comparison with vehicle (Veh, n = 3). The results are presented as the means ± SEMs. *p < 0.05, **p < 0.01.

  • Open Access

    Table S4 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response

    by Inês Gomes, Maria Martelo, Rúben D. Vilela, María Jiménez, Eva M. Trinidad, Jorge Gómez-Miragaya, Eva González-Suárez, Érica Martins, Sofia S. Torres, Patrícia Corredeira, et al.

    Supplementary Table 4. HALLMARK gene set enrichment analysis (H-GSEA) of mouse xenografts (NES>1 or <-1; NOM p value<0.05; FDR q value<0.25).

  • Open Access

    Table S2 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response

    by Inês Gomes, Maria Martelo, Rúben D. Vilela, María Jiménez, Eva M. Trinidad, Jorge Gómez-Miragaya, Eva González-Suárez, Érica Martins, Sofia S. Torres, Patrícia Corredeira, et al.

    Differentially expressed genes (DEGs) between treated (OPG-Fc n = 2; Palbo n = 2; COMB n = 3) and untreated (Vehicle, n = 3) MDA-MB-231 xenografts, ranked according to Log2FC (log2>1 or <-1; FDR q value<0.1). (.xls file)

  • Open Access

    Data from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response

    by Inês Gomes, Maria Martelo, Rúben D. Vilela, María Jiménez, Eva M. Trinidad, Jorge Gómez-Miragaya, Eva González-Suárez, Érica Martins, Sofia S. Torres, Patrícia Corredeira, et al.

    Despite chemotherapy’s limitations and toxic effects, it remains the primary treatment for most patients with triple-negative breast cancer (TNBC), with or without immune checkpoint inhibitors. Although cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy have revolutionized luminal breast cancer treatment, CDK4/6is alone are largely ineffective in TNBC, even with functional retinoblastoma protein (pRB). Activation of the receptor activator of nuclear factor κB (RANK) pathway has been associated with poor prognosis in TNBC and with resistance to CDK4/6is in luminal breast cancer, effects that can be reversed by RANK ligand inhibitors (RANKLi). In this study, we analyzed the effect of RANK knockdown or RANKLi in the response of pRB-proficient TNBC to CDK4/6i in vitro. RANK + patient-derived xenograft and cell line–derived xenograft models were used to assess therapeutic efficacy of CDK4/6i + RANKLi in vivo. Two syngeneic models of TNBC and luminal breast cancer were used to portrait the main therapy-induced alterations in the tumor immune microenvironment. RANK knockdown or RANKLi sensitized pRB-proficient TNBC cells to CDK4/6i in vitro. The combination of palbociclib and RANKLi regressed or prevented tumor growth and metastasis in vivo, enhancing cell cycle arrest. Both CDK4/6i and RANKLi elicited an antitumor immune response, characterized by an increase in CD4+ and CD8+ T cells and a decrease in tumor-associated macrophages infiltrating the tumor microenvironment. These findings suggest that combining CDK4/6i and RANKLi could offer a new therapeutic strategy for pRB-proficient TNBC, holding potential immunomodulatory benefits across breast cancer subtypes.

  • Open Access

    Figure S3 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response

    by Inês Gomes, Maria Martelo, Rúben D. Vilela, María Jiménez, Eva M. Trinidad, Jorge Gómez-Miragaya, Eva González-Suárez, Érica Martins, Sofia S. Torres, Patrícia Corredeira, et al.

    Supplementary Figure 3 (related to Fig. 3). Palbociclib in combination with OPG-Fc decreases the growth of palbociclib-resistant tumors in vivo and induces an inflammatory response. A, Rank expression in murine BC cell lines retrieved from CCLE (n = 4). B, Proliferation of the indicated cell lines cultured in the presence of CDK4/6i for 7 days and in drug-free media for an additional 7 days, as measured by a clonogenic assay (n = 3-4 independent experiments). C, Tumor weight at sacrifice (n = 4-8 tumors). D, Quantification of TRAcP5b in mouse serum by ELISA (n = 3 samples/group). E, Mouse body weight during treatment (n = 4-5 animals). The results are presented as the means ± SEMs. *p < 0.05, **p < 0.01.